口服司美格鲁肽对比恩格列净治疗二甲双胍控制不佳的2型糖尿病:PIONEER 2试验
PIONEER 2试验将二甲双胍控制不佳的2型糖尿病患者随机分配至口服司美格鲁肽14 mg或恩格列净25 mg治疗52周。主要终点第26周HbA1c降幅口服司美格鲁肽优于恩格列净(治疗策略估计:-1.3% vs -0.9%,ETD -0.4% [95%CI -0.6, -0.3],P<0.0001),但体重下降未确认优效;第52周两药HbA1c及体重(试验产品估计)均有显著差异。胃肠道不良事件口服司美格鲁肽更常见,安全性在GLP-1受体激动剂已知范围内。
要点
- 口服司美格鲁肽14 mg降低HbA1c优于恩格列净25 mg。
- 第26周体重下降未确认优效,第52周试验产品估计下体重降幅更优。
- 胃肠道不良事件口服司美格鲁肽更常见,总体耐受性良好。
核心结论
- 在二甲双胍控制不佳的2型糖尿病患者中,口服司美格鲁肽降低HbA1c优于恩格列净,但第26周体重下降未确认优效。
- 第52周时,口服司美格鲁肽在试验产品估计下HbA1c和体重均显著优于恩格列净。
研究设计与样本
- 52周随机、开放标签试验,患者随机接受每日一次口服司美格鲁肽14 mg(n=412)或恩格列净25 mg(n=410)。
- 主要终点为第26周HbA1c自基线变化,确证性次要终点为体重变化;采用治疗策略和试验产品两种估计量。
主要发现
- 第26周HbA1c降幅(治疗策略估计):口服司美格鲁肽-1.3% vs 恩格列净-0.9%(-14 vs -9 mmol/mol),ETD -0.4% [95%CI -0.6, -0.3](-5 mmol/mol [-6, -3]),P<0.0001。
- 第26周HbA1c降幅(试验产品估计):-1.4% vs -0.9%(-15 vs -9 mmol/mol),ETD -0.5% [95%CI -0.7, -0.4](-6 mmol/mol [-7, -5]),P<0.0001。
- 第52周HbA1c在两种估计下均显著优于恩格列净(P<0.0001)。
- 第26周体重下降(治疗策略估计)未确认优效;第52周试验产品估计体重降幅-4.7 vs -3.8 kg,P=0.0114。
临床怎么用
- 对于二甲双胍控制不佳的2型糖尿病,口服司美格鲁肽可显著改善血糖控制。
- 需关注胃肠道不良反应,但总体安全性符合GLP-1受体激动剂已知特征。
局限性
- 开放标签设计可能影响主观终点评估。
- 52周疗程不足以评估长期硬终点。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium-glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin. RESEARCH DESIGN AND METHODS: Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands addressed efficacy-related questions: treatment policy (regardless of trial product discontinuation or rescue medication) and trial product (on trial product without rescue medication) in all randomized patients. RESULTS: Four hundred (97.1%) patients in the oral semaglutide group and 387 (94.4%) in the empagliflozin group completed the trial. Oral semaglutide provided superior reductions in HbA1c versus empagliflozin at week 26 (treatment policy -1.3% vs. -0.9% [-14 vs. -9 mmol/mol], estimated treatment difference [ETD] -0.4% [95% CI -0.6, -0.3] [-5 mmol/mol (-6, -3)]; P < 0.0001). The treatment difference in HbA1c significantly favored oral semaglutide at week 26 for the trial product estimand (-1.4% vs. -0.9% [-15 vs. -9 mmol/mol], ETD -0.5% [95% CI -0.7, -0.4] [-6 mmol/mol (-7, -5)]; P < 0.0001) and at week 52 for both estimands (P < 0.0001). Superior weight loss was not confirmed at week 26 (treatment policy), but oral semaglutide was significantly better than empagliflozin at week 52 (trial product -4.7 vs. -3.8 kg; P = 0.0114). Gastrointestinal adverse events were more common with oral semaglutide. CONCLUSIONS: Oral semaglutide was superior to empagliflozin in reducing HbA1c but not body weight at 26 weeks in patients with type 2 diabetes uncontrolled on metformin. At week 52, HbA1c and body weight (trial product estimand) were significantly reduced versus empagliflozin. Oral semaglutide was well tolerated within the established safety profile of GLP-1 receptor agonists.
引用
- Rodbard HW, Rosenstock J, Canani LH, et al. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial. Diabetes Care. 2019. PMID: 31530666. doi:10.2337/dc19-0883
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。